PCOS Is Now Called PMOS — Here's What Actually Changed

PCOS Didn't Change — the Name Did

Polycystic ovary syndrome (PCOS) is now officially polyendocrine metabolic ovarian syndrome, or PMOS. The change was published as a multistep global consensus in The Lancet in May 2026, led by Monash University's Professor Helena Teede alongside more than 50 patient and professional organizations, including the Endocrine Society and the American Society for Reproductive Medicine.

If you already have a PCOS diagnosis, nothing about your care changes automatically. The diagnostic criteria, the treatment options, and the biology of the condition are the same — this was a renaming, not a redefinition. A three-year transition period is underway, so expect to see PCOS and PMOS used interchangeably in your doctor's office, in research, and online for a while yet.

Why Change a Name That's Been Used for a Century

Patient advocacy groups pushed for the change after surveys found the old name led to confusion — and, in some cases, delayed diagnosis.

The core problem with "polycystic ovary syndrome" was the word "cystic." What shows up on an ultrasound in PCOS/PMOS isn't a collection of true, pathological cysts — it's a higher number of small, immature ovarian follicles that haven't fully matured. Decades of both patients and clinicians misunderstanding this led to real confusion about what the condition actually was, and the name's narrow focus on the ovaries also obscured its wider effects on metabolism, insulin resistance, cardiovascular risk, and mental health.

The renaming process took more than a decade and drew on over 22,000 survey responses from patients and healthcare professionals worldwide. According to reporting on the consensus paper, the large majority of both groups supported moving to a name that better reflects the condition's full, systemic impact rather than one built around a single, and somewhat inaccurate, ultrasound finding.

Why "Metabolic" Is Now Part of the Name

The word "metabolic" in the new name isn't cosmetic — it reflects a body of research that's been building for years showing PCOS/PMOS is as much an endocrine and metabolic condition as a reproductive one. Insulin resistance affects a large share of people with the condition regardless of body weight, and it's a central driver of many PCOS symptoms, not just a common co-occurring issue. Elevated insulin pushes the ovaries to produce more androgens, which in turn worsens the classic symptoms most people associate with PCOS: irregular periods, acne, and excess hair growth. That feedback loop is a metabolic story as much as a reproductive one, and it's part of why treatment has always extended well beyond fertility management into things like metformin, dietary changes, and exercise that target insulin sensitivity directly.

The renaming also formally acknowledges elevated long-term cardiovascular and type 2 diabetes risk as core features of the condition rather than side notes. That's a meaningful shift for how the condition gets discussed with patients: a diagnosis under the new framing is more likely to prompt a conversation about long-term metabolic monitoring, not just menstrual cycle regulation or fertility planning, even for patients who aren't currently trying to conceive.

Your Diagnosis and Treatment Aren't Changing

In practice, expect a slow rollout. Some clinics and countries will adopt PMOS quickly; others will keep using PCOS for years out of habit or because systems (insurance codes, patient records, research databases) take time to update. Neither term is "more correct" to use with your own doctor right now — they both refer to the exact same condition.

How the Condition Is Actually Diagnosed

The diagnostic framework, commonly called the Rotterdam criteria, hasn't changed under the new name and is worth understanding on its own terms since it's what your doctor is actually working from. A diagnosis typically requires meeting at least two of three features: irregular or absent ovulation, clinical or lab-confirmed signs of elevated androgens (like excess hair growth or acne, or elevated testosterone on bloodwork), and the characteristic ultrasound appearance of the ovaries. Notably, you don't need all three, and you don't need the ovarian finding at all to be diagnosed — a point that's often lost given how central "polycystic" was to the old name.

This two-out-of-three structure is also why PCOS/PMOS presentations vary so widely between patients. Someone with irregular cycles and elevated androgens but a normal-looking ultrasound qualifies for diagnosis just as much as someone with the classic ultrasound picture, which is part of why the condition has historically been both underdiagnosed and inconsistently diagnosed across different clinicians and countries.

Frequently Asked Questions